


Life Without Limitations










Össur 2010 1 Copyright Ossur



Life Without Limitations









HIGHLIGHTS Q2 2010



Sales USD 90 m

Double digit growth

- All segments growing
- Overall 12% growth, LCY

OperationsEBITDA USD 20 m

Profits remain strong

- Gross profit margin 62%
- EBITDA margin 22%

Highlights

Key highligths

- Good performance across all markets
- California offices consolidated into one location

AMERICAS Q2 2010 - EXCELLENT GROWTH



Life Without Limitations

Americas 52% of total sales

- Sales growth 12%
- Continued strong prosthetics growth
- Excellent B&S sales growth
 - → Momentum in functional bracing
 - → Shifting from custom made to off the shelf products
 - → Success of new products



Note: All growth numbers in local currency excluding Team Makena

EMEA Q2 2010 - ACCORDING TO PLAN





EMEA 44% of total sales

- Sales growth 7%
- Strong prosthetics growth
- Bracing and supports growing in line with market growth
- Compression therapy 5%, above market growth
- Acquisition of OP Africa, Össur's B&S distributor in South Africa
- Success in Leipzig, the largest O&P tradeshow in Europe

Note: All growth numbers in local currency

ASIA Q2 2010 - CONTINUES TO DELIVER



Life Without Limitations

Asia 4% of total sales

- Sales growth 13%
- Both segments performing well
- Building a strong platform



Note: All growth numbers in local currency

SUCCESSFUL B&S PRODUCT PIPELINE



Life Without Limitations

Product launches YTD:

Miami Lumbar Rigid lumbar belt



Miami Lumbar TLSO



ReSolve Halo Vest



Miami J Advanced



Rebound Walker



Innovator DLX



• Q1

Techform Premium & Standard



Formfit 45



•• Q2

PROSTHETIC PRODUCT PIPELINE REMAINS STRONG



Life Without Limitations

Product launches YTD:

Iceross Comfort Cushion



Iceross Dermo Cushion



Iceross Synergy Cushion



Flex-Foot Balance



Total Knee 1100



Total Knee 2100



Q1

Iceross Comfort Wave








Q2



Life Without Limitations









FINANCIAL HIGHLIGHTS Q2 2010



- Excellent growth
- Good profits

INCOME STATEMENTS Q2 2010




Income Statements (USD millions)	Q2 2010	% of sales	Q2 2009	% of sales	Change	%change
Net sales	90.0	100.0%	81.3	100.0%	8.7	10.7%
Gross profit	55.6	61.7%	50.1	61.5%	5.5	11.0%
Operating expenses	-39.5	-43.9%	-38.3	-47.1%	-1.2	3.1%
Profit from operations	16.0	17.8%	11.8	14.5%	4.2	35.6%
Net profit	13.6	15.1%	2.4	2.9%	11.2	466.7%
EBITDA	19.6	21.7%	17.0	20.8%	2.6	15.3%
EBITDA adjusted*	20.0	22.3%	17.9	22.0%	2.1	11.7%

^{*2009} Adjusted for one-time expenses: USD 1.0 million *2010 Adjusted for one-time expenses: USD 0.5 million

SALES – EXCELLENT DEVELOPMENT





- Good sales growth across all segments
- B&S sales growth:
 - Americas above market
 - EMEA in line with market
- Prosthetics, continued success
- Moderate growth expected in Q3/Q4

Note: Organic LCY growth excludes acquisitions

SALES GROWTH BY SEGMENTS Q2 2010



Sales by region / segments	Growth USD	Growth LCY	Organic growth LCY *
Americas	19%	18%	12%
EMEA	2%	7%	7%
Asia	17%	13%	13%
Total	11%	12%	10%
Prosthetics	14%	15%	15%
Bracing and supports	10%	11%	6%
Compression therapy	0%	7%	5%
Total	11%	12%	10%

^{*} Excluding acquired entities

GROSS PROFIT – CONSISTENT PERFORMANCE








OPERATING EXPENSES – STABLE






- S&M Expanding sales platforms
- R&D Consistent investment
- G&A Flat in absolute terms

EXCHANGE RATE MOVEMENTS – VOLATILE



Life Without Limitations


FINANCIAL ITEMS: NET EXCHANGE RATE DIFFERENCES





NET PROFIT - INCREASING






- Net profit up by USD 11.2 million
- Significant exchange rate impact
- Growth driving profits

EBITDA MARGIN – 22%







CASH FLOW



Life Without Limitations

CASH GENERATED BY OPERATIONS






CAPEX – BELOW BENCHMARK







BALANCE SHEETS 30 JUNE 2010




Life Without Limitations

USD'000	30. June '10	31. Dec '09
Non current assets	417,279	448,446
Current assets	162,870	179,771
Total assets	580,149	628,217
Stockholders' equity	311,510	312,223
Non current liabilities	193,330	237,045
Current liabilities	75,309	78,949
Total equity and liabilities	580,149	628,217
Current ratio	2.2	2.3
Equity ratio	54%	50%
Net interest bearing debt / EBITDA	1.8	2.4



FINANCIAL HIGHLIGHTS Q2 2010






- Excellent growth
- Good profits



Life Without Limitations









Guidance – Management estimates LCY organic sales growth will be at the top end, or even slightly above the previously guided range of 4-6% for the full year. LCY organic EBITDA growth is expected to be above 10%

Guidance 2010

Sales growth (LCY): 4 - 6%

EBITDA growth: (LCY) >10%

WE IMPROVE PEOPLE'S MOBILITY



Listed on NASDAQ OMX Copenhagen

www.ossur.com

ÖSSUR

Life Without Limitations*